Strategic Acquisition Helps Build Tonix€™s Commercial Capabilities and Infrastructure Ahead of Potential Launch of TNX-102 SL for the Management of Fibromyalgia Acquisition of Zembrace® SymTouch®...
Cipla gets USFDA nod for migraine drug
Drug major Cipla on Tuesday said it has received final approval from the United States Food and Drug Administration (USFDA) for Sumatriptan Nasal Spray, indicated for the treatment of migraine attacks.
Cipla`s Generic Sumatriptan Receives Approval In US
Perrigo UK Finco's Generic Sumatriptan Receives Approval In US
Perrigo UK Finco's Generic Sumatriptan Receives Approval In US
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI;OTCQX: NRIFF), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that its wholly owned subsidiary, Aralez Pharmaceuticals Canada Inc. (Aralez Canada) has received a Notice of Compliance from Health Canada for Suvexx™. Suvexx (sumatriptan succinate and naproxen sodium tablets) is a fixed-dose combination prescription medication, indicated for the acute treatment of migraine attacks with or without aura in adults. Aralez Canada anticipates launching Suvexx into the approximately $130 million Canadian prescription acute migraine market in the second half of 2020.
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Tosymra™ (sumatriptan) Nasal Spray, 10 mg for the acute treatment of migraine with or without aura in adults. Tosymra is a fast-acting, easy-to-use acute migraine treatment option that delivers the efficacy of an injectable in a convenient nasal spray.
Currax Pharmaceuticals LLC, a specialty biopharmaceutical company with both Branded and generic business units, announced today a deal whereby Currax obtained patent rights to ONZETRA® Xsail® (sumatriptan nasal powder) in North America from OptiNose AS, a subsidiary of OptiNose, Inc. (Nasdaq: OPTN)